Ali Behbahani, M.D. has served as a member of our board of directors since January 2015. Dr. Behbahani joined New Enterprise Associates (NEA), a venture capital firm, in 2007 and is currently a Partner and the Co-Head of Healthcare. Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners from 2000 to 2002 and as a Healthcare Investment Banking Analyst at Lehman Brothers from 1998 to 2000. Dr. Behbahani has been a member of the board of directors of Adaptimmune Therapeutics Plc (Nasdaq: ADAP) since September 2014, Black Diamond Therapeutics (Nasdaq: BDTX) since December 2018, CRISPR Therapeutics AG (Nasdaq: CRSP) since March 2015, Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) since April 2020, Nkarta, Inc. (Nasdaq: NKTX) since August 2015 and Korro Bio, Inc. (Nasdaq: KRRO) since August 2019. Dr. Behbahani previously served as a member of the board of directors of CVRx, Inc. (Nasdaq: CVRX) from July 2013 to September 2024, Genocea Biosciences (Nasdaq: GNCA) from February 2018 to May 2022, Minerva Surgical, Inc. (Nasdaq: UTRS) from May 2011 to January 2024, and Oyster Point Pharma (Nasdaq: OYST) from July 2017 to January 2023. Dr. Behbahani received a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University, an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine. We believe that Dr. Behbahani is qualified to serve on our board due to his experience in life sciences and his experience as a member of the boards of directors of multiple companies in the life science industry.